Kepler Capital Markets Reiterates GBX 6,570 Price Target for AstraZeneca (AZN)

Share on StockTwits

AstraZeneca (LON:AZN) has been assigned a GBX 6,570 ($85.85) target price by equities research analysts at Kepler Capital Markets in a research note issued on Wednesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Kepler Capital Markets’ price objective indicates a potential upside of 7.69% from the company’s current price.

AZN has been the subject of a number of other research reports. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research note on Monday, January 21st. JPMorgan Chase & Co. reiterated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, January 22nd. Liberum Capital reiterated a “hold” rating on shares of AstraZeneca in a research note on Friday, March 29th. Goldman Sachs Group set a GBX 4,080 ($53.31) target price on shares of AstraZeneca and gave the stock a “sell” rating in a research note on Tuesday, January 1st. Finally, Societe Generale boosted their target price on shares of AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the stock a “buy” rating in a research note on Wednesday, January 16th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of GBX 6,307.70 ($82.42).

Shares of AZN stock opened at GBX 6,101 ($79.72) on Wednesday. The company has a debt-to-equity ratio of 136.31, a current ratio of 0.96 and a quick ratio of 0.71. The firm has a market cap of $80.25 billion and a P/E ratio of 35.89. AstraZeneca has a 12 month low of GBX 4,850 ($63.37) and a 12 month high of GBX 6,540 ($85.46).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: What is the yield curve?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Greene King’s  “Buy” Rating Reiterated at Peel Hunt
Greene King’s “Buy” Rating Reiterated at Peel Hunt
Telecom plus  Stock Rating Reaffirmed by Peel Hunt
Telecom plus Stock Rating Reaffirmed by Peel Hunt
Smart Metering Systems’  Buy Rating Reiterated at Peel Hunt
Smart Metering Systems’ Buy Rating Reiterated at Peel Hunt
Travis Perkins  Earns “Hold” Rating from Peel Hunt
Travis Perkins Earns “Hold” Rating from Peel Hunt
Peel Hunt Reaffirms “Add” Rating for Marshalls
Peel Hunt Reaffirms “Add” Rating for Marshalls
Peel Hunt Reaffirms “Buy” Rating for Countryside Properties
Peel Hunt Reaffirms “Buy” Rating for Countryside Properties


© 2006-2019 Ticker Report